This metabolite includes a PDE selectivity profile comparable to sildenafil and an in vitro potency for PDE5 about fifty% from the guardian drug. Plasma concentrations of this metabolite are somewhere around forty% of These witnessed for sildenafil, so which the metabolite accounts for about 20% of sildenafil's pharmacologic outcomes.Medicines are